## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.3% in mid entry zone (3.0-6.0%), top quartile (85th pct) cross-sectional ranking. Short-term MRS_5 (4.3%) confirms momentum alignment. Strong momentum (+6.3% 5-day acceleration). Outperforming sector by 3.6%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($100.44)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma**
- Source: TradingView — Track All Markets | 20260106T150809 | Bullish | Relevance: 100%
- Incyte announced positive top-line results from its Phase III frontMIND study for Monjuvi/Minjuvi (tafasitamab) in combination with Bristol Myers’ Revlimid and R-CHOP for newly diagnosed diffuse large B-cell lymphoma (DLBCL). The study met its primary endpoint of statistically meaningful improvement in progression-free survival and its key secondary endpoint of event-free survival, with no new safety signals. Incyte plans to submit a supplemental biologics license application to the FDA in the first half of 2026 for label expansion for first-line DLBCL treatment.

**2. Aggressive lymphoma trial: tafasitamab combo meets key survival goals**
- Source: Stock Titan | 20260105T123236 | Bullish | Relevance: 100%
- Incyte announced positive topline results from its pivotal Phase 3 frontMIND trial, showing that tafasitamab and lenalidomide combined with R-CHOP met the primary endpoint of progression-free survival in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The trial also achieved its key secondary endpoint of event-free survival, with no new safety signals observed. These results indicate a potential new treatment option for high-risk DLBCL patients, leading Incyte to plan a supplemental Biologics License Application filing in the first half of 2026.

**3. Incyte reports positive data from tafasitamab Phase III trial for DLBCL**
- Source: Yahoo Finance | 20260106T040600 | Bullish | Relevance: 100%
- Incyte announced positive top-line data from its Phase III frontMIND trial, showing that tafasitamab combined with lenalidomide and R-CHOP met its primary endpoint of progression-free survival in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. The company plans to submit a supplemental biologics license application (sBLA) for tafasitamab as a first-line therapy for DLBCL in the first half of 2026. This development could offer a new treatment option for high-risk DLBCL patients, an adult non-Hodgkin lymphoma.

**4. Incyte’s tafasitamab meets primary endpoint in frontMIND trial By Investing.com**
- Source: Investing.com Australia | 20260105T130823 | Bullish | Relevance: 100%
- Incyte (NASDAQ:INCY) announced that its Phase 3 frontMIND trial for tafasitamab in first-line diffuse large B-cell lymphoma (DLBCL) treatment met its primary endpoint of progression-free survival. The trial also achieved its key secondary endpoint of event-free survival with no new safety signals. Incyte plans to submit a supplemental Biologics License Application for tafasitamab in first-line DLBCL treatment in the first half of 2026.

**5. Incyte’s tafasitamab meets primary endpoint in frontMIND trial By Investing.com**
- Source: Investing.com UK | 20260105T120816 | Bullish | Relevance: 100%
- Incyte announced its Phase 3 frontMIND trial for tafasitamab in combination with lenalidomide and R-CHOP for first-line diffuse large B-cell lymphoma (DLBCL) treatment met its primary endpoint of progression-free survival. The company plans to file a supplemental Biologics License Application in the first half of 2026 based on these positive results. This news follows Incyte's recent European Commission approval for Minjuvi in relapsed or refractory follicular lymphoma, and analyst firms have maintained their ratings on the company.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-06 | Morgan Stanley | $94 | $92 | +2% |
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-06 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 18 ($30.49M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Heavy insider selling: $30M sold (18 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +16%) could attract flows.
- Momentum building: MRS_10 improving +6.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +16%). Insider selling cluster ($30.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.9B |
| Beta | 0.82 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 7.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 13.9 |
| Current P/E | 15.8 |
| YoY Growth | 13.7% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -1.0% to 5.3% (+6.3% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 85th percentile. MRS_5 at 4.3% confirms short-term momentum alignment. Outperforming sector by 3.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.58), confirming momentum. OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.28% (CS: 86) | Strong |
| RSI_14 | 66.4 | Neutral |
| MACD Histogram | 0.58 | Bullish |
| vs SMA20 | 1.077x | Above |
| vs SMA50 | 1.060x | Above |
| vs SMA200 | 1.340x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $106.66
- **Stop Loss:** $100.44 (5.8% risk)
- **Target:** $115.99 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 212
- **Position Value:** $22,611.92
- **Portfolio %:** 22.61%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*